Sangamo Therapeutics Inc (NASDAQ: SGMO) kicked off on Tuesday, down -4.58% from the previous trading day, before settling in for the closing price of $0.85. Over the past 52 weeks, SGMO has traded in a range of $0.29-$1.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 17.84% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 68.83%. With a float of $198.81 million, this company’s outstanding shares have now reached $208.22 million.
In an organization with 405 employees, it is important to assess its efficiency. In terms of profitability, gross margin is -43.29%, operating margin of -2021.56%, and the pretax margin is -2024.16%.
Sangamo Therapeutics Inc (SGMO) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Sangamo Therapeutics Inc is 4.52%, while institutional ownership is 41.86%. The most recent insider transaction that took place on Sep 26 ’23, was worth 3,000,000. In this transaction 10% Owner of this company sold 6,000,000 shares at a rate of $0.50, taking the stock ownership to the 17,652,466 shares.
Sangamo Therapeutics Inc (SGMO) Latest Financial update
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.59 earnings per share (EPS), lower than consensus estimate (set at -0.32) by -0.27. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 68.83% per share during the next fiscal year.
Sangamo Therapeutics Inc (NASDAQ: SGMO) Trading Performance Indicators
Take a look at Sangamo Therapeutics Inc’s (SGMO) current performance indicators. Last quarter, stock had a quick ratio of 1.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.38, a number that is poised to hit -0.01 in the next quarter and is forecasted to reach -0.23 in one year’s time.
Technical Analysis of Sangamo Therapeutics Inc (SGMO)
Let’s dig in a bit further. During the last 5-days, its volume was 3.28 million. That was inferior than the volume of 6.67 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 35.97%. Additionally, its Average True Range was 0.12.
During the past 100 days, Sangamo Therapeutics Inc’s (SGMO) raw stochastic average was set at 53.40%, which indicates a significant increase from 17.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.78% in the past 14 days, which was lower than the 135.82% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6565, while its 200-day Moving Average is $0.6115. However, in the short run, Sangamo Therapeutics Inc’s stock first resistance to watch stands at $0.8681. Second resistance stands at $0.9269. The third major resistance level sits at $0.9740. If the price goes on to break the first support level at $0.7622, it is likely to go to the next support level at $0.7151. The third support level lies at $0.6563 if the price breaches the second support level.
Sangamo Therapeutics Inc (NASDAQ: SGMO) Key Stats
The company with the Market Capitalisation of 168.49 million has total of 207,510K Shares Outstanding. Its annual sales at the moment are 176,230 K in contrast with the sum of -257,830 K annual income. Company’s last quarter sales were recorded 360 K and last quarter income was -36,130 K.
